Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2023-188655

Published: 2023

Journal Articles

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Blood (2023) 141 (11): 1308–1315.

https://doi.org/10.1182/blood.2022017863

Published: 2023

Includes: Supplemental data

Journal Articles

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

Laure Vincent, Anne Charvet-Rumpler, Lotfi Benboubker, Claire Calmettes, Anne-Marie Stoppa, Kamel Laribi, Lauriane Clement Filliatre, Fressia Honeyman, Richez Valentine, Cyrille Hulin, Frédéric Maloisel, Margaret Macro, Lionel Karlin, Vanessa Barué, Christos Chouaid, Hacène Zerazhi, Xavier Leleu

Blood (2022) 140 (Supplement 1): 4312–4314.

https://doi.org/10.1182/blood-2022-157942

Published: 2022

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 4668–4670.

https://doi.org/10.1182/blood-2022-162682

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Blood (2022) 139 (17): 2666–2672.

https://doi.org/10.1182/blood.2021014968

Published: 2022

Includes: Supplemental data

Journal Articles

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Blood (2021) 138 (25): 2686–2695.

https://doi.org/10.1182/blood.2021011285

Published: 2021

Includes: Supplemental data

Journal Articles

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Blood (2021) 138 (Supplement 1): 82.

https://doi.org/10.1182/blood-2021-147897

Published: 2021

Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal

Blood (2021) 138 (Supplement 1): 464.

https://doi.org/10.1182/blood-2021-146040

Published: 2021

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Blood (2021) 138 (Supplement 1): 485.

https://doi.org/10.1182/blood-2021-152391

Published: 2021

Journal Articles

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Blood (2021) 138 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2021-152136

Published: 2021

Journal Articles

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

Lauriane Clement-Filliatre, MD, Lotfi Benboubker, MD, Anne-Marie Stoppa, Philippe Rodon, MD, Kamel Laribi, MD, Laure Vincent, Philippe Collet, Valentine Richez, MD, Anne Charvet-Rumpler, Hacene Zerazhi, MD, Cyrille Hulin, MD, Frederic Maloisel, MD PhD, Margaret Macro, Lionel Karlin, MD, Nathalie Texier, Christos Chouaid, Xavier Leleu, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-133807

Published: 2020

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Blood (2020) 135 (18): 1531–1540.

https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1836.

https://doi.org/10.1182/blood-2019-124484

Published: 2019

Journal Articles

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Blood (2019) 134 (Supplement_1): 4614.

https://doi.org/10.1182/blood-2019-128004

Published: 2019

Journal Articles

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Margaux Damge, Sabine Furst, MD, Bénédicte Devictor, Samia Harbi, MD, Joseph Ciccolini, Angela Granata, MD, Thomas Pagliardini, MD, Boris Calmels, Pharm.D., Claude Lemarie, Pharm.D., Luca Castagna, MD, Valerio Maisano, MD, Faezeh Legrand, MD, Anne-Marie Stoppa, MD, Reda Bouabdallah, Evelyne D'Incan, Norbert Vey, MD PhD, Christian Chabannon, MD PhD, Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2019) 134 (Supplement_1): 4503.

https://doi.org/10.1182/blood-2019-125994

Published: 2019

Journal Articles

Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Murielle Roussel, MD, Benjamin Hebraud, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Thierry Facon, MD, Eileen Boyle, MD PhD, Cyrille Touzeau, MD PhD, Brigitte Pegourie, MD, Aurore Perrot, MD PhD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Philippe Moreau, MD, Herve Avet-Loiseau, MD PhD, Laure Devlamynck, Valerie Lauwers-Cances, MD, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3159.

https://doi.org/10.1182/blood-2019-123184

Published: 2019

Journal Articles

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Blood (2018) 132 (24): 2555–2563.

https://doi.org/10.1182/blood-2018-07-863829

Published: 2018

Includes: Supplemental data

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Blood (2018) 132 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2018-99-111892

Published: 2018

NARROW

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only